Company profile
BiomX Inc.
AMEX:PHGEBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05240300 | phase1_2 | withdrawn | 2022-05-01 | 2023-06-01 | BiomX, Inc. | A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis |
| NCT04737876 | phase1 | completed | 2020-10-28 | 2020-12-21 | BiomX, Inc. | A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults |
| NCT05010577 | phase1_2 | completed | 2022-06-21 | 2024-03-10 | BiomX, Inc. | Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection |
| NCT06998043 | phase2 | recruiting | 2025-07-02 | 2026-03-01 | BiomX Ltd | Study With Phage for CF Subjects With Pseudomonas Lung Infection |
FDA applications (0)
No records yet.